Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<p>Positive news flow surrounding COVID-19 is encouraging on many fronts. Still, despite encouraging news and the relief rally in global equities, history tells us that this is a fairly standard bear market rally in terms of its magnitude, making us believe the global equity market is not yet out of the woods. We are watching for signs of a turn of the tide. There has been significant damage inflicted and that damage is going to take time to repair. Actionable Themes in this report have representation in Staples, Health Care, Technology, and a collection of bottom-up ideas. </p>

Positive news flow surrounding COVID-19 is encouraging on many fronts. Still, despite encouraging news and the relief rally in global equities, history tells us that this is a fairly standard bear market rally in terms of its magnitude, making us believe the global equity market is not yet out of the woods. We are watching for signs of a turn of the tide. There has been significant damage inflicted and that damage is going to take time to repair. Actionable Themes in this report have representation in Staples, Health Care, Technology, and a collection of bottom-up ideas. 

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<p>In our first insight, we covered the company's background, particularly its management team and its product pipeline.In this insight, we will discuss valuation and deal specific details. </p><h2>Thoughts on Valuation</h2><p>Given the limited drug candidates product pipeline and lack of income, we think the SOTP based on risk adjusted NPV valuation is a suitable valuation method for Zai Lab. Our valuation will encompass the following assumptions for each product:</p><ul><li>Annual case: We will take this number from the…</li></ul>

In our first insight, we covered the company's background, particularly its management team and its product pipeline.In this insight, we will discuss valuation and deal specific details. Thoughts on ValuationGiven the limited drug candidates product pipeline and lack of income, we think the SOTP based on risk adjusted NPV valuation is a suitable valuation method for Zai Lab. Our valuation will encompass the following assumptions for each product:Annual case: We will take this number from the…

Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)

<p>Zai Lab is looking to raise US$100m in the US listing. The company has a short history of three years and does not have a commercial product at the moment. In this insight, we will look at its history, team, product pipelines. In our follow up insight, we will look at its valuation. </p><h2>Company Background</h2><p>Zai Lab (再鼎医药) was founded in 2014 by experienced biopharmaceutical industrial practitioners. The company assembled a pipeline consisting of six drug candidates through partnerships with global…</p>

Zai Lab is looking to raise US$100m in the US listing. The company has a short history of three years and does not have a commercial product at the moment. In this insight, we will look at its history, team, product pipelines. In our follow up insight, we will look at its valuation. Company BackgroundZai Lab (再鼎医药) was founded in 2014 by experienced biopharmaceutical industrial practitioners. The company assembled a pipeline consisting of six drug candidates through partnerships with global…

Zai Lab IPO: Experienced Team, Promising In-Licensing Drug Pipeline (Part 1)

China

Betta Pharmaceuticals Co., Ltd operates as a pharmaceutical company. The Company researches, manufactures, and sells drugs for the treatment of malignant tumors, diabetes, cardiovascular, cerebrovascular, and other related diseases. Betta Pharmaceuticals markets throughout China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Betta Pharmaceuticals (300558 CH)

Major Indexes Testing Resistance

Positive news flow surrounding COVID-19 is encouraging on many fronts. Still, despite encouraging news and the relief rally in global equities,...

Vermilion Research

Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)

In our first insight, we covered the company's background, particularly its management team and its product pipeline.In this insight, we will...

Ke Yan, CFA, FRM

Zai Lab IPO: Experienced Team, Promising In-Licensing Drug Pipeline (Part 1)

Zai Lab is looking to raise US$100m in the US listing. The company has a short history of three years and does not have a commercial product at the...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)